One year ago – on April 7, 2022 – the Centers for Medicare & Medicaid Services (CMS) announced that it would refuse to cover an entire class of FDA-approved therapies for the treatment of mild cognitive impairment and early dementia due to Alzheimer's disease. CMS' decision effectively cut off access for the vast majority of beneficiaries living with early Alzheimer's, except those wealthy seniors who could choose to pay out-of-pocket.
Read Full Article »
